ABSTRACT Introduction: Human immune deficiency viruses (HIV), Hepatitis B viruses (HBV) and Hepatitis C viruses (HCV) are the three most common chronic viral pathogens known. The viruses have common routes of transmission (such as blood and blood products, sharing needles to inject drugs and sexual activities) and similar risk factors. Aim and objective: The aim of study was to determine the seroprevalence of HIV, HBV and HCV in Kohalpur Teaching Hospital, Nepalgunj Medical College. Materials and methods: This is a descriptive hospital based study. The study was conducted at Nepalgunj Medical College, KTH, Banke. In this study, 2865 were tested for HIV, 2849 were tested for HBV and 2950 were tested for HCV from 12-01-2017 to 06-07-2017. Results: In case of HIV, 1781 (62.16%) were male and 1064 (37.84%) were female. The study revealed that in HIV reactive case was found to be 0.14% where 0.16% (3) were males and 0.09% (1) were females. In case of HBV, 1743 (61.18%) were males and 1106 (38.82%) were females. The prevalence of HBV reactive was found to be 1.65% where 1.2% (34) in male and 0.45% (13) in female. In case of HCV, 1200 (40.67%) were male and 1750 (59.33%) were female. The prevalence of HCV reactive was found to be 0.03% (1) which was only in female. Conclusion: We found that the prevalence of HIV was more predominant in males 0.16% (3). The HBV was more prevalent followed by HIV and HCV and the prevalence of HBV in male was more 1.2% (34) as compared to females 0.45% (13).
INTRODUCTION
Human immune deficiency viruses (HIV), Hepatitis B viruses (HBV) and Hepatitis C viruses (HCV) are the three most common chronic viral pathogens known. Despite their biological differences and natural history of chronic infection, the viruses have common routes of transmission (such as blood and blood products, sharing needles to inject drugs and sexual activities) and similar risk factors 1 
.
The HIV is the etiologic agent of AIDS. AIDS was first recognized clinically in 1981, although the first known case of AIDS has been traced to1959. HIV exists as two major viral species; HIV-1 and HIV-2. HIV-1 was initially discovered in 1983 and HIV-2 in . HIV/AIDS has had a great impact on society, both as an illness and as a source of discrimination. The disease also has large economic impacts. There are many misconceptions about HIV/AIDS such as the belief that it can be transmitted by casual non-sexual contact. There is no cure or vaccine available as on date, however, antiretroviral treatment can slow the course of the disease and may lead to a nearnormal life expectancy. Treatment is recommended as soon as the diagnosis is made. Without treatment, the average survival time after infection may be around 10 years Hepatitis B virus (HBV) is a member of the hepadnavirus family. HBs Ag (also known as the Australia antigen) is the surface antigen of the hepatitis B virus (HBV). It indicates current hepatitis B infection. This is because it was first isolated by the American research physician and Nobel Prize winner Baruch S. Hepatitis C is an infection that mostly affects the liver. Often, a person with Hepatitis C does not have any symptoms. However, chronic infection can scar the liver. Many years of infection may cause cirrhosis. Sometimes, people with cirrhosis also have liver failure or liver cancer. They can also have very swollen veins of the oesophagus and stomach. Scientists began studying the Hepatitis C virus in the 1970s, and in 1989 they proved that the virus exists. As far as scientists know, this virus does not cause disease in any animals other than humans. The medications that are normally used to treat Hepatitis C are called peg interferon and ribavirin. Between 50-80% of people who are treated (5 to 8 out of every 10) are cured. However, if a person's Hepatitis C has progressed (or gotten worse) so much that the person has cirrhosis or liver cancer, the person might need a liver transplant. This makes it possible for the person to survive, but the Hepatitis C virus usually comes back after the transplant. There is no vaccine that works to prevent people from getting Hepatitis C 3 .
Total global HCV prevalence is estimated at 2.5% (177.5 million of HCV infected adults), ranging from 2.9% in Africa and 1.3% in Americas, with a global viraemic rate of 67% (118.9 million of HCV RNA positive cases), varying from 64.4% in Asia to 74.8% in Australia 6 .
MATERIALS AND METHODS
This was a descriptive hospital based study, 2865 were tested for HIV, 2849 were tested for HBV and 2950 were tested for HCV, attending to Nepalgunj Medical College, KTH, Nepal, were investigated for HBV, HCV and HIV from 12-01-2017 to 06-07-2017. The prevalence of HBV, HCV ad HIV in the male was compared with that in the female.
HIV test
Tri Dot test is manufactured and marketed by DIAGNOSTIC ENTERPRISES, (de@diagnosticenterprises.com).
Based on flow through technology, HIV TRI-DOT test is a visual, rapid, sensitive and accurate immunoassay for the differential detection of HIV-1 and HIV-2 antibodies (IgG) in Human Serum or Plasma using HIV-1 and HIV-2 Antigens immobilized on an immunofiltration membrane. The test is a screening test for anti-HIV-1 and anti-HIV-2 and is for in vitro diagnostic use only. HIV TRI-DOT has been developed and designed using gp41, C-t e r m i n u s o f g p 1 2 0 a n d g p 3 6 re p re s e n t i n g t h e immunodominant regions of HIV-1 & HIV-2 envelope gene structure respectively.
The test is named for the three dots that appear to give the result: one pink dot is a control dot, showing the test is functioning properly; one dot shows the presence of HIV-1 antibodies and one dot shows the presence of HIV-2 antibodies. The 4 th generation HCV TRI-DOT has been developed and designed with increased sensitivity for core and NS3 antibodies using a unique combination of modified HCV antigens. They are for the putative core (structural), protease/helicase NS3 (nonstructural), NS4 (non-structural) and replicase NS5 (nonstructural) regions of the virus in the form of two test dots "T 1 " &"T 2 " to provide a highly sensitive and specific diagnostic test. The test is named for the three dots that appear to give the result: one pink dot is a control dot, either pink dot on each "T 1 " &"T 2 " or both regions indicate that the specimen is reactive for antibodies to HCV.
HBV

RESULTS
Our study has aimed to determine the seroprevalence of HIV, HBV and HCV. In the present study, 2865 patients were tested for HIV, 2849 patients were tested for HBV and 2950 patients were tested for HCV, attending to Nepalgunj Medical College, KTH, and Nepal.
Among 2865 patients who were tested for HIV, 1781 (62.16%) were male and 1084 (37.84%) were female. The prevalence of HIV reactive was found to be 0.14% (4) where 0.16% (3) in male and 0.09% (1) in female. Out of 2849 were tested for HBV, 1743 (61.18%) were male and 1106 (38.82%) were female. The prevalence of HBV reactive was found to be 1.65% (47) where 1.2% (34) in male and 0.45% (13) in female.
Similarly, out of 2950 were tested for HCV, 1200 (40.67%) were male and 1750 (59.33%) were female. The prevalence of HCV reactive was found to be 0.03% (1) which was only in female. A study done in Nepal showed the prevalence of HBV and HCV were 2.1% and 0.33% respectively 13 . Another study of the seroprevalence of HCV was 0.66% 14 . In Our study, the prevalence of HIV was 0.13%, HBV was 1.65% and HCV was 0.03% among 1865, 2849 and 2950 patients attending the hospital, which are not very different from the previous studies done in different parts of Nepal. The prevalence was higher in HBV followed by HIV and HCV. The prevalence in male was seen higher in HIV and HBV but the prevalence was higher in female seen in HCV.
CONCLUSION
The seroprevalence of HIV was 0.14% in 2864, HBV was 1.65% in 2849 and HCV was 0.03% in 2950. HBV was more prevalent followed by HIV and HCV in the Mid-Western part on Nepal who visited in Nepalgunj Medical College, Kohalpur Teaching Hospital. Higher prevalence was seen in males than in females in HIV and HBV. In HCV, reactive cases were seen only in one female not in male.
HIV/AIDS is the burning crisis worldwide. However, the approach for the management of the issue is dissimilar in different countries. In low prevalence countries like Nepal, the Government of Nepal could deliver the different prevention activities. The disease management and prevention is necessary. Since HIV, HBV and HCV infections have high mortality; population at risk should be screened to know the burden of infections nationwide to make the plans and policies for disease prevention.
